Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Marisela Jimenez-Sanchez

Evaluation of the Efficacy and Safety of Switching to Pasireotide in Patients With Acromegaly Inadequately Controlled With First-Generation Somatostatin Analogs

Frontiers in Endocrinology
EndocrinologyMetabolismDiabetes
2020English

Related publications

Trial Design of Phase IIIb, Open-Label, Single Arm Study to Evaluate Efficacy and Safety of Pasireotide LAR in Patients With Inadequately-Controlled Acromegaly Despite Treatment With First-Generation Somatostatin Analogues

Endocrine Abstracts
2015English

Postoperative Use of Somatostatin Analogs and Mortality in Patients With Acromegaly.

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2019English

Efficacy and Safety of Diacerein in Patients With Inadequately Controlled Type 2 Diabetes: A Randomized Controlled Trial

Diabetes Care
Internal MedicineEndocrinologyAdvancedMetabolismSpecialized NursingDiabetes
2017English

Interpreting Biochemical Control Response Rates With First-Generation Somatostatin Analogues in Acromegaly

Pituitary
EndocrinologyMetabolismDiabetes
2015English

Added Value of Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Predicting Response to Somatostatin Analogs in Patients With Acromegaly

Turkish Neurosurgery
SurgeryNeurology
2019English

Progress in the Formulation and Delivery of Somatostatin Analogs for Acromegaly

Therapeutic Delivery
Pharmaceutical Science
2017English

What Is the Efficacy of Switching to Weekly Pegvisomant in Acromegaly Patients Well Controlled on Combination Therapy?

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2016English

Efficacy of the New Long-Acting Formulation of Lanreotide (Lanreotide Autogel) in Somatostatin Analogue-Naive Patients With Acromegaly

Journal of Endocrinological Investigation
EndocrinologyMetabolismDiabetes
2009English

Combined Treatment for Acromegaly With Long-Acting Somatostatin Analogs and Pegvisomant: Long-Term Safety for Up to 4.5 Years (Median 2.2 Years) of Follow-Up in 86 Patients

European Journal of Endocrinology
MedicineEndocrinologyMetabolismDiabetes
2009English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy